UCDAVIS HEALTH | Department of Pathology and Laboratory Medicine

Interference and Point-of-Care Testing Devices

SCHOOL OF MEDICINE

Nam K. Tran, PhD, HCLD, (ABB), FACB
Associate Clinical Professor
Director of Clinical Chemistry, Special Chemistry/Toxicology and POCT

Learning Objectives

- Identify common interferences affecting POC testing
- Describe cases where interfering substances affected patient care.
- Describe solutions to mitigate the impact of interfering substances on POC testing.

POCT Device Formats

Definition: POCT is defined as testing at or near the site of patient care



POCT Device Formats

Examples:

- Disposable
- Handheld
- Portable
- Transportable
- Benchtop
- Monitoring



POCT Device Formats

Examples:

- Disposable
- Handheld
- Portable
- Transportable
- Benchtop
- Monitoring

Being FDA approved as a POCT device does not mean it is not susceptible to interfering substances!!!



Total Testing Process: Difference Phases

Total Testing Process: Lab testing occurs over three critical phases:

Pre-Analytical

Total Testing Process: Difference Phases

Total Testing Process: Lab testing occurs over three critical phases:

Total Testing Process: Difference Phases

Total Testing Process: Lab testing occurs over three critical phases:

Total Testing Process: Difference Phases

Total Testing Process: Lab testing occurs over three critical phases:

Total Testing Process: Sources of Error

Errors in the Pre-Analytical Phase: Most frequent source of errors (up to 70%). Incorrect

Total Testing Process: Sources of Error

Errors in the Pre-Analytical Phase: Most frequent source of errors (up to 70%). Incorrect

Total Testing Process: Sources of Error

Errors in the Analytical Phase: Infrequent in laboratory tests, however may be higher in POCT due to non-lab trained personnel operating devices.

Components

Patient preparation
Sample collection
Transportation
Accessioning
Processing

Testing

Pre-Analytical	Analytical	Post-Analytical	TREATMENT

Sources of Error

Incorrect patient ID
Mislabeling of specimens
Hemolysis
Wrong specimen type
Improper specimen collection
Interfering substances

Total Testing Process: Sources of Error

Errors in the Analytical Phase: Infrequent in laboratory tests, however may be higher in POCT due to non-lab trained personnel operating devices.

	Pre-Analytical	Analytical	Post-Analytical	TREATMENT
Components	Patient preparation Sample collection Transportation Accessioning Processing	Testing		
Sources of Error	Incorrect patient ID Mislabeling of specimens Hemolysis Wrong specimen type Improper specimen collection Interfering substances	QC/calibration Operator error Bad reagents		

Total Testing Process: Sources of Error

Errors in the Post-Analytical Phase: Second most common among laboratory-based results.



Total Testing Process: Sources of Error

Errors in the Post-Analytical Phase: Second most common among laboratory-based results.

	Pre-Analytical	Analytical	Post-Analytical	TREATMENT
Components	Patient preparation Sample collection Transportation Accessioning Processing	Testing	Results interpretation Entry to LIS/EMR Contacting providers Sample archiving	
Sources of Error	Incorrect patient ID Mislabeling of specimens Hemolysis Wrong specimen type Improper specimen collection Interfering substances	QC/calibration Operator error Bad reagents	Misinterpretation of results IT problems	

Total Testing Process: Sources of Error

Errors in the Post-Analytical Phase: Second most common among laboratory-based results.

	Pre-Analytical	Analytical	Post-Analytical	TREATMENT
Components	Patient preparation Sample collection Transportation Accessioning Processing	Testing	Results interpretation Entry to LIS/EMR Contacting providers Sample archiving	
Sources of Error	Incorrect patient ID Mislabeling of specimens Hemolysis Wrong specimen type Improper specimen collection Interfering substances	QC/calibration Operator error Bad reagents	Misinterpretation of results IT problems	

What is the significance of testing error in POCT?

Glucose Meter Paradigm to Highlight the Role of Testing Errors

Glucose Meter Paradigm to Highlight the Role of Testing Errors

>12,000 glucose meter errors are reported to the FDA each year – highest number of adverse events for any in vitro diagnostic device.

Glucose Meter Paradigm to Highlight the Role of Testing Errors

>12,000 glucose meter errors are reported to the FDA each year – highest number of adverse events for any in vitro diagnostic device.

12,672 serious injuries reported from 2004-2008 to the FDA.

Glucose Meter Paradigm to Highlight the Role of Testing Errors

>12,000 glucose meter errors are reported to the FDA each year – highest number of adverse events for any in vitro diagnostic device.

12,672 serious injuries reported from 2004-2008 to the FDA.

Most of these reported errors are due to erroneous results from interfering substances and operator error.

Glucose Meter Paradigm to Highlight the Role of Testing Errors



Most of these reported errors are due to erroneous results from interfering substances and operator error.

Glucose Meter Paradigm to Highlight the Role of Testing Errors



Most of these reported errors are due to erroneous results from **interfering substances** and operator error.

Common Confounding Factors for Glucose Meters



Anemia and polycythemia causes falsely high or falsely low results respectively.



Hematocrit Effects on BGMS Measurements



Note: Bias = BGMS – Plasma Glucose

Common Confounding Factors for Glucose Meters





Common Confounding Factors for Glucose Meters

Oxidizing and reducing substances interfere with electrochemical sensors causing falsely high or low results.







Tang Z, et al. *Am J Clin Pathol* 2000;113:75-86

The role of drug interferences in critical care BGMS accuracy

Tran NK, et al. *J Burn Care Res* 2014;35:72-79

CASE EXAMPLE: ASCORBIC ACID INTERFERENCE



CASE EXAMPLE: ASCORBIC ACID INTERFERENCE



CASE EXAMPLE: ASCORBIC ACID INTERFERENCE



Common Confounding Factors for Glucose Meters



Common Confounding Factors for Glucose Meters

Specimen temp alters biosensor enzyme kinetics. Hypotension/shock affect capillary specimens.



Common Confounding Factors for Glucose Meters

Some glucose meters cannot differentiate between certain non-glucose sugars (e.g., maltose, galactose)



Non-Glucose Sugar Interferences

- Icodextrin is a dialysis drug. It is metabolized by the body to maltose. In some glucose biosensors, maltose is indistinguishable from glucose.





From Pharmacotherapy

Interference of Maltose, Icodextrin, Galactose, or Xylose with Some Blood Glucose Monitoring Systems

Thomas G. Schleis, M.S.

Authors and Disclosures

Posted: 10/04/2007; Pharmacotherapy. 2007;27(9):1313-1321.

Abstract and Introduction

Abstract

Maltose, a disaccharide composed of two glucose molecules, is used in a number of biological preparations as a stabilizing agent or osmolality regulator. Icodextrin, which is converted to maltose, is present in a peritoneal dialysis solution. Galactose and xylose are found in some foods, herbs, and dietary supplements; they are also used in diagnostic tests. When some blood glucose monitoring systems are used—specifically, those that use test strips

Abstract and Introduction

Labeling Requirements for Maltose-Containing Products

Galactose and Xylose

Pharmacology and Pharmacokinetics of Maltose

Discussion

Conclusion

References

Maltose Related Deaths



	BGMS A	BGMS B	BGMS C
Timeframe	1997-14	2013-14	2007-11
Adverse Events (Deaths)	28 (13)	5 (0)	0 (0)
Erroneous Results	557	168	15
Non-Clinical Event	387	59	21
TOTAL	1094	232	36

FDA MAUDE Database website: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfmaude/ search.cfm, Accessed on August 20, 2014

Continuous Glucose Monitors?

- Similar sensor designs so susceptible to similar interferences (will vary based on manufacturer).
- CGM based on interstitial fluid measurements and not plasma or whole blood.
- Potential for many other sources of interferences.
- CGM does not fall under CLIA and most devices compared against obsolete or poor reference methods such as the YSI.
- **Use WITH caution!**

INTERFERENCES IN WHOLE BLOOD ANALYSIS

INTERFERENCES IN WHOLE BLOOD ANALYSIS

Air Contamination

Delayed Testing

Hemodilution/Hemoconcentration

Hemolysis

INTERFERENCES IN WHOLE BLOOD ANALYSIS

Air Contamination

Delayed Testing

Hemodilution/Hemoconcentration

Hemolysis

Air Contamination of Blood Specimens

Background: Anesthesia reports “impossible venous blood gas values” in one patient where end tidal CO2 was greater than the venous blood gas (VBG).

Air Contamination of Blood Specimens

Background: Anesthesia reports “impossible venous blood gas values” in one patient where end tidal CO2 was greater than the venous blood gas (VBG).

- POC Venous Blood Gas: pH = 7.54, pCO2 = 17.5, pO2 = **168.5**
- POC VBG#2: pH = 7.56, pCO2 = 12.7, pO2 = **165.9**
- End tidal CO2 = 28

Air Contamination of Blood Specimens

Background: Anesthesia reports “impossible venous blood gas values” in one patient where end tidal CO2 was greater than the venous blood gas (VBG).

- POC Venous Blood Gas: pH = 7.54, pCO2 = 17.5, pO2 = **168.5**
- POC VBG#2: pH = 7.56, pCO2 = 12.7, pO2 = **165.9**
- End tidal CO2 = 28
- Lab Venous Blood Gas: pH 7.54, pCO2 = 19.2, pO2 = **161.5**

Air Contamination of Blood Specimens

Background: Anesthesia reports “impossible venous blood gas values” in one patient where end tidal CO2 was greater than the venous blood gas (VBG).

- POC Venous Blood Gas: pH = 7.54, pCO2 = 17.5, pO2 = **168.5**
- POC VBG#2: pH = 7.56, pCO2 = 12.7, pO2 = **165.9**
- End tidal CO2 = 28
- Lab Venous Blood Gas: pH 7.54, pCO2 = 19.2, pO2 = **161.5**

Blood Gas Laboratory identified “air bubbles” in syringe

Air Contamination of Blood Specimens

Background: Anesthesia reports “impossible venous blood gas values” in one patient where end tidal CO2 was greater than the venous blood gas (VBG).

- POC Venous Blood Gas: pH = 7.54, pCO2 = 17.5, pO2 = **168.5**
- POC VBG#2: pH = 7.56, pCO2 = 12.7, pO2 = **165.9**
- End tidal CO2 = 28
- Lab Venous Blood Gas: pH 7.54, pCO2 = 19.2, pO2 = **161.5**
- **Air bubbles can quickly (<5 mins) cause the specimen to equilibrate atmospheric air (1 atm = 760 mmHg = 0.21 x 760 = 150 mmHg for pO2!!!)**

INTERFERENCES IN BLOOD GAS ANALYSIS

Air Contamination

Delayed Testing

Hemodilution/Hemoconcentration

Hemolysis

Specimen Processing Delays and Lactate

Pre-Analytical

- Transportation delays

Analysis should be performed within 20 to 30 minutes—Faster is better!

Specimen Processing Delays and Lactate

Pre-Analytical

- Transportation delays



Seymour CW, et al. BMC Research Notes 2011;4:169

Specimen Processing Delays and Lactate

Pre-Analytical

- Transportation delays
- Inadequate inhibition of glycolysis

If delays are expected, using a grey top tube may be appropriate, however it may take up to 15 minutes to achieve inhibition!



Specimen Processing Delays and Lactate

Pre-Analytical

- Transportation delays
- Inadequate inhibition of glycolysis



Fig. 2. Lactate stability in whole blood at room temperature with F vs OX. Heparinized blood was obtained from a normal volunteer and then split into aliquots that received 60 mmol/L F (□), 12 mmol/L OX (●), both additives (+), or neither (■).

Astles R, et al. Clin Chem 1994;404:1327

Specimen Processing Delays and Lactate

Pre-Analytical

- Transportation delays
- Inadequate inhibition of glycolysis



Fig. 1. Effectiveness of F/OX in samples from patients with leukocytosis. Samples were evaluated from three patients with increased neutrophil counts due to granulocyte colony-stimulating factor, and a fourth patient with a carcinoma-associated leukemoid reaction. EDTA-anticoagulated whole blood was stored at room temperature with (*closed symbols*) and without F/OX (*open symbols*). Neutrophil counts were 51.7 (✥), 52.5 (○), 27.1 (□), and 23(△) × 10^9/L.

Astles R, et al. Clin Chem 1994;404:1327

Specimen Processing Delays and Lactate

Pre-Analytical

- Transportation delays
- Inadequate inhibition of glycolysis
- Specimens not placed on ice

False elevations of lactate could be mitigated by placing samples on ice. Iced samples exhibit similar results to those tested immediately at up to 6 hours.

Specimen Processing Delays and Lactate

Pre-Analytical

- Transportation delays
- Inadequate inhibition of glycolysis
- Specimens not placed on ice



Seymour CW, et al. BMC Research Notes 2011;4:169

INTERFERENCES IN WHOLE BLOOD ANALYSIS

Air Contamination

Delayed Testing

Hemodilution/Hemoconcentration

Hemolysis

Contemporary Hemoglobinometric Techniques

- **Spectrophotometric (Non-Cyanohemoglobin)**



- Measurement of hemoglobin is based on the absorption spectra
- Oxy- and deoxyhemoglobin exhibit different absorption in the red to IR wavelengths.
- Measurement based on Beer's Law (A = elc).
- Some methods require lysis and reacting with non-cyanide-based reagents.

Contemporary Hemoglobinometric Techniques

Conductance (Impendance)

- Red blood cell membranes are not conductive.

Contemporary Hemoglobinometric Techniques

Conductance (Impendance)

Electrode



VS.

- Red blood cell membranes are not conductive.



Contemporary Hemoglobinometric Techniques

Conductance (Impendance)

Electrode



VS.

- Red blood cell membranes are not conductive.
- The number of red blood cells is proportional to the change in conductance and conforms to Ohm's Law (V = IR)

Contemporary Hemoglobinometric Techniques

Conductance (Impendance)

Electrode



VS.

- Red blood cell membranes are not conductive.
- The number of red blood cells is proportional to the change in conductance and conforms to Ohm's Law (V = IR)
- Conductance-based methods measure hematocrit. The hematocrit can then be used to calculate hemoglobin based on a conversion factor (estimated hemoglobin = hematocrit / 3.4)*

Contemporary Hemoglobinometric Techniques

Conductance (Impendance)

Electrode



VS.

Case Study 2: Hemoconcentration

Background: Patient with suspected Ebola Virus symptoms admitted for evaluation. Isolation protocols were in effect.



Case Study 2: Hemoconcentration

Background: Patient with suspected Ebola Virus symptoms admitted for evaluation. Isolation protocols were in effect.

Case Study 2: Hemoconcentration

Background: Patient with suspected Ebola Virus symptoms admitted for evaluation. Isolation protocols were in effect. A handheld blood gas chemistry analyzer served as the primary chemistry analyzer.

0853 hrs – Specimens collected for chemistry and CBC testing.

Case Study 2: Hemoconcentration

Background: Patient with suspected Ebola Virus symptoms admitted for evaluation. Isolation protocols were in effect. A handheld blood gas chemistry analyzer served as the primary chemistry analyzer.

0853 hrs – Specimens collected for chemistry and CBC testing.

Case Study 2: Hemoconcentration

Background: Patient with suspected Ebola Virus symptoms admitted for evaluation. Isolation protocols were in effect. A handheld blood gas chemistry analyzer served as the primary chemistry analyzer.

0853 hrs – Specimens collected for chemistry and CBC testing.

Case Study 2: Hemoconcentration

Background: Patient with suspected Ebola Virus symptoms admitted for evaluation. Isolation protocols were in effect. A handheld blood gas chemistry analyzer served as the primary chemistry analyzer.

0853 hrs – Specimens collected for chemistry and CBC testing.

Handheld Results
Hct = 68%
Hb = 21.9 g/dL

Case Study 2: Hemoconcentration

Background: Patient with suspected Ebola Virus symptoms admitted for evaluation. Isolation protocols were in effect. A handheld blood gas chemistry analyzer served as the primary chemistry analyzer.

0853 hrs – Specimens collected for chemistry and CBC testing.

Handheld Results
Hct = 68%
Hb = 21.9 g/dL

CBC Results
Hct = 41%
Hb = 13.2 g/dL

Case Study 2: Hemoconcentration

Background: Patient with suspected Ebola Virus symptoms admitted for evaluation. Isolation protocols were in effect. A handheld blood gas chemistry analyzer served as the primary chemistry analyzer.

0853 hrs – Specimens collected for chemistry and CBC testing.

Handheld Results
Hct = 68%
Hb = 21.9 g/dL

RE-MIXING!

Hct = 43%
Hb = 13.8 g/dL

CBC Results
Hct = 41%
Hb = 13.2 g/dL

Case Study 2: Hemoconcentration

Background: Patient with suspected Ebola Virus symptoms admitted for evaluation. Isolation protocols were in effect. A handheld blood gas chemistry analyzer served as the primary chemistry analyzer.

0853 hrs – Specimens collected for chemistry and CBC testing.

Handheld Results
Hct = 68%
Hb = 21.9 g/dL

RE-MIXING!

Hct = 43%
Hb = 13.8 g/dL

CBC Results
Hct = 41%
Hb = 13.2 g/dL

Inadequate mixing may result in artificial changes in total hemoglobin measurements.

Contemporary Hemoglobinometric Techniques

Conductance (Impendence)

= Plasma Protein

Electrode



High Resistance

- Plasma protein content contributes to hematocrit measurements for conductance-based systems.

Contemporary Hemoglobinometric Techniques

Conductance (Impendence)

= Plasma Protein

Electrode



Low Resistance from low plasma protein concentration!

- Plasma protein content contributes to hematocrit measurements for conductance-based systems.
- Conductance-based systems assumes a relatively fixed protein concentration. Therefore, during hemodilution, hematocrit may be falsely lower and causing an underestimation of total hemoglobin.

Contemporary Hemoglobinometric Techniques

Conductance (Impendence)

= Plasma Protein

Electrode



- Plasma protein content contributes to hematocrit measurements for conductance-based systems.
- Conductance-based systems assumes a relatively fixed protein concentration. Therefore, during hemodilution, hematocrit may be falsely lower and causing an underestimation of total hemoglobin.
- **UCDMC Study:** Comparison of a handheld blood gas analyzer using conductance-based measurement of hemoglobin versus a benchtop blood gas analyzer using a spectrophotometric-based method for hemoglobinometry.

Clinical Impact of Hemodilution for Point-of-Care Hemoglobin Measurements

- Sixty patients requiring cardiac surgery were evaluated.
- Paired specimens were tested using a handheld POC analyzer and spectrophotometric methods through the core laboratory.
- Mean (SD) bias was -1.4 (1.1) g/dL, P = 0.011.
- Based on core laboratory results 12 patients would have received unnecessary transfusions.



Clinical Impact of Hemodilution for Point-of-Care Hemoglobin Measurements

- Sixty patients requiring cardiac surgery were evaluated.
- Paired specimens were tested using a handheld POC analyzer and spectrophotometric methods through the core laboratory.
- Mean (SD) bias was -1.4 (1.1) g/dL, P = 0.011.
- Based on core laboratory results 12 patients would have received unnecessary transfusions.



Clinical Impact of Hemodilution for Point-of-Care Hemoglobin Measurements

- Sixty patients requiring cardiac surgery were evaluated.
- Paired specimens were tested using a handheld POC analyzer and spectrophotometric methods through the core laboratory.
- Mean (SD) bias was -1.4 (1.1) g/dL, P = 0.011.
- Based on core laboratory results 12 patients would have received unnecessary transfusions.

= $219

$219 x 12 = $2,628
POTENTIALLY WASTED

Toner RW, et al. Appl Health Econ Health Policy 2011;9:29-37

Case Study 3: Hemodilution



Case Study 3: Hemodilution

Background: FDA MAUDE database reports a case (03P76-25) of a neonatal patient with discrepant point-of-care (POC) hemoglobin values compared to the laboratory. The POC device used a conductance-based method of hemoglobin measurement, while the laboratory used a spectrophotometric method.

Case Study 3: Hemodilution

Background: FDA MAUDE database reports a case (03P76-25) of a neonatal patient with discrepant point-of-care (POC) hemoglobin values compared to the laboratory. The POC device used a conductance-based method of hemoglobin measurement, while the laboratory used a spectrophotometric method.

- POC device reported a hematocrit of 22%. Physician administered 7 mL of blood based on the POC result.

Case Study 3: Hemodilution

Background: FDA MAUDE database reports a case (03P76-25) of a neonatal patient with discrepant point-of-care (POC) hemoglobin values compared to the laboratory. The POC device used a conductance-based method of hemoglobin measurement, while the laboratory used a spectrophotometric method.

- POC device reported a hematocrit of 22%. Physician administered 7 mL of blood based on the POC result.

- Transfusion was stopped halfway after the laboratory reported a hematocrit of 40% and hemoglobin of 11.7 g/dL.

Case Study 3: Hemodilution

Background: FDA MAUDE database reports a case (03P76-25) of a neonatal patient with discrepant point-of-care (POC) hemoglobin values compared to the laboratory. The POC device used a conductance-based method of hemoglobin measurement, while the laboratory used a spectrophotometric method.

- POC device reported a hematocrit of 22%. Physician administered 7 mL of blood based on the POC result.
- Transfusion was stopped halfway after the laboratory reported a hematocrit of 40% and hemoglobin of 11.7 g/dL.
- Post-transfusion POC and lab hematocrit values were 45 and 50% respectively.

Analytical Performance of Optical vs. Conductance-Based Hemoglobinometry



Analytical Performance of Optical vs. Conductance-Based Hemoglobinometry



Analytical Performance of Optical vs. Conductance-Based Hemoglobinometry



Analytical Performance of Optical vs. Conductance-Based Hemoglobinometry







Notes: Reference Method = Beckman LH hematology analyzer

Analytical Performance of Optical vs. Conductance-Based Hemoglobinometry





Median (IQR) Bias: 0.78 (0.78) g/dL
P < 0.001
N = 50

Notes: Reference Method = Beckman LH hematology analyzer

Analytical Performance of Optical vs. Conductance-Based Hemoglobinometry





Median (IQR) Bias: 0.73 (0.60) g/dL
P < 0.001
N = 50

Notes: Reference Method = Beckman LH hematology analyzer

Analytical Performance of Optical vs. Conductance-Based Hemoglobinometry





Median (IQR) Bias: 0.22 (0.20) g/dL
P = 0.510
N = 50

Notes: Reference Method = Beckman LH hematology analyzer

Analytical Performance of Optical vs. Conductance-Based Hemoglobinometry



Serial Testing Performance at 7 and 8 g/dL

- Serial testing revealed significant analytical bias between spectrophotometry vs. conductance-based measurements.

Spectrophotometric-based Methods

Notes: *** P<0.001, Central Lab = Spectrophotometric Method, n = 20 patients

Analytical Performance of Optical vs. Conductance-Based Hemoglobinometry



Serial Testing Performance at 7 and 8 g/dL

- Serial testing revealed significant analytical bias between spectrophotometry vs. conductance-based measurements.

Spectrophotometric-based Methods

Conductance-based Methods

Notes: *** P<0.001, Central Lab = Spectrophotometric Method, n = 20 patients

Analytical Performance of Optical vs. Conductance-Based Hemoglobinometry



Serial Testing Performance at 7 and 8 g/dL

- Serial testing revealed significant analytical bias between spectrophotometry vs. conductance-based measurements.
- Conductance-based devices would have prompted unnecessary transfusions at time point #5 for patients using the 7 g/dL cutoff.

Notes: *** P<0.001, Central Lab = Spectrophotometric Method, n = 20 patients

Analytical Performance of Optical vs. Conductance-Based Hemoglobinometry



Serial Testing Performance at 7 and 8 g/dL

- Serial testing revealed significant analytical bias between spectrophotometry vs. conductance-based measurements.
- Conductance-based devices would have prompted unnecessary transfusions at time point #5 for patients using the 7 g/dL cutoff.
- All serial conductance measurements were at risk for potential transfusions if the 8 g/dL cutoff was used.

Notes: *** P<0.001, Central Lab = Spectrophotometric Method, n = 20 patients

Analytical Performance of Optical vs. Conductance-Based Hemoglobinometry



Serial Testing Performance at 7 and 8 g/dL

- Serial testing revealed significant analytical bias between spectrophotometry vs. conductance-based measurements.
- Conductance-based devices would have prompted unnecessary transfusions at time point #5 for patients using the 7 g/dL cutoff.
- All serial conductance measurements were at risk for potential transfusions if the 8 g/dL cutoff was used.

Notes: *** P<0.001, Central Lab = Spectrophotometric Method, n = 20 patients

Manufacturer and User Facility Device Experience (MAUDE) Database Summary

	Device 1	Device 2	Device 3
Timeframe	2011-2016	2011-2016	2014-2016*
Erroneous Results	8	0	0
Improper Transfusions	5	0	0

https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfmaude/results.cfm, Accessed on July 19, 2016

INTERFERENCES IN WHOLE BLOOD ANALYSIS

Air Contamination

Delayed Testing

Hemodilution/Hemoconcentration

Hemolysis

INTERFERENCES IN WHOLE BLOOD ANALYSIS

Air Contamination

Delayed Testing

Hemodilution/Hemoconcentration

Hemolysis



INTERFERENCES IN WHOLE BLOOD ANALYSIS

Air Contamination

Delayed Testing

Hemodilution/Hemoconcentration

Hemolysis



INTERFERENCES IN WHOLE BLOOD ANALYSIS

Air Contamination

Delayed Testing

Hemodilution/Hemoconcentration

Hemolysis



No current FDA approved integrated solutions for detecting hemolysis at the point-of-care

Pseudohyperkalemia
“Pseudonormokalemia”

Biotin: The “Snake Oil” of 2018?



Safety Communications

2018 Safety Communications

2017 Safety Communications

The FDA Warns that Biotin May Interfere with Lab Tests: FDA Safety Communication

Date Issued: November 28, 2017

Product:

Many lab tests use biotin technology due to its ability to bond with specific proteins which can be measured to detect certain health conditions. For example, biotin is used in hormone tests and tests for markers of cardiac health like troponin. Biotin, also known as vitamin B7, is a water-soluble vitamin often found in multi-vitamins, prenatal vitamins, and dietary supplements marketed for hair, skin, and nail growth.

Biotin and Cardiac Troponin Testing

Estimating the Probability of Biotin Interference

- 1,443 Gen 5 troponin T samples tested (0-hour, n = 797; 3-hour, n=646) from 850 patients.



*There was a statistically significant difference between 0-hour and 3-hour biotin concentrations (p<0.001; paired Wilcoxon rank sum test).

Mumma B, et al. AACC Poster Presentation 2018

Estimating the Probability of Biotin Interference

- 1,443 Gen 5 troponin T samples tested (0-hour, n = 797; 3-hour, n=646) from 850 patients.
- Biotin not detectable in 471 (59%) and 399 (62%) 3-hour samples.



*There was a statistically significant difference between 0-hour and 3-hour biotin concentrations (p<0.001; paired Wilcoxon rank sum test).

Mumma B, et al. AACC Poster Presentation 2018

Estimating the Probability of Biotin Interference

- 1,443 Gen 5 troponin T samples tested (0-hour, n = 797; 3-hour, n=646) from 850 patients.
- Biotin not detectable in 471 (59%) and 399 (62%) 3-hour samples.
- Only one 0-hour sample and one 3-hour sample had biotin >20 ng/mL (0.13% [95% CI: 0-0.7%]).



*There was a statistically significant difference between 0-hour and 3-hour biotin concentrations (p<0.001; paired Wilcoxon rank sum test).

Mumma B, et al. AACC Poster Presentation 2018

Estimating the Probability of Biotin Interference



Mumma B, et al. AACC Poster Presentation 2018

Estimating the Probability of Biotin Interference



UC Davis Cardiac Troponin Patients

Adult ED Patients with Unknown Biotin Status: **540**

Average Plasma Biotin: 1.15 (0.97) ng/mL

Specimens collected as part of clinical validation

UC Davis Cardiac Troponin Patients



Adult ED Patients with Unknown Biotin Status: 540

Average Plasma Biotin: 1.15 (0.97) ng/mL



Gen 5 TnT Biotin Interference Threshold is 20 ng/mL

Biotin quantified by GC-TOF-MS

UC Davis Cardiac Troponin Patients



Adult ED Patients with Unknown Biotin Status: 540

Average Plasma Biotin: 1.15 (0.97) ng/mL



BIOTIN IS LESS LIKELY TO BE A PROBLEM IN CARDIAC TROPONIN TESTING AND IS POPULATION SPECIFIC!

Gen 5 TnT Biotin Interference Threshold is 20 ng/mL

Biotin quantified by GC-TOF-MS

Biotin and Urine Pregnancy Testing

Biotin Interference with Urine Pregnancy Tests



- Recent studies show some point-of-care urine pregnancy tests were affected by biotin.
- Biotin is cleared by the kidneys.
- In this study, the QuickVue urine pregnancy test exhibited interference as low as 6 microgram/mL of urine biotin!

Williams G, et al. Clin Biochem 2018;53:168-170

Best POCT Practices for Mitigating Interfering Substances

POCT Best Practices for Interferences

- **Education:** The laboratory must be the leader in educating providers **and patients** of potential test interferences. Go to grand rounds, build partnerships, and provide multi-modality means to disseminate knowledge.

POCT Best Practices for Interferences

- **Education:** The laboratory must be the leader in educating providers **and patients** of potential test interferences. Go to grand rounds, build partnerships, and provide multi-modality means to disseminate knowledge.

POCT Best Practices for Interferences

- **Education:** The laboratory must be the leader in educating providers **and patients** of potential test interferences. Go to grand rounds, build partnerships, and provide multi-modality means to disseminate knowledge.

- **Surveillance:** Know your population! Collect data and determine if your local population may be be at risk for certain interferences (e.g., biotin, vitamin C, etc). MAUDE database is also helpful!

POCT Best Practices for Interferences

- **Education:** The laboratory must be the leader in educating providers of potential test interferences. Go to grand rounds, build partnerships, and provide multi-modality means to disseminate knowledge.

- **Surveillance:** Know your population! Collect data and determine if your local population may be be at risk for certain interferences (e.g., biotin, vitamin C, etc). MAUDE database is also helpful!

- **Electronic Early-Warning Systems:** Leverage electronic solutions. Ordering of susceptible tests could flag both on the provider and laboratory side certain substances are identified.

Conclusions

- Interfering substances are out there and impact POC testing as much as traditional lab testing!
- Interferences in common POC devices such as glucose meters have resulted in injury and death.
- Interferences in whole blood analysis have resulted in inappropriate treatment decisions.
- Medications and supplements may also affect POC immunoassays such as urine pregnancy tests.
- Education and awareness is critical to minimizing errors associated with interfering substances.

Questions?